Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Creation of Apolipoprotein C-II (ApoC-II) Mutant Mice and Correction of Their Hypertriglyceridemia with an ApoC-II Mimetic Peptide.

The Journal of pharmacology and experimental therapeutics - 1 Feb 2016

Sakurai Toshihiro, Sakurai Akiko, Vaisman Boris L, Amar Marcelo J, Liu Chengyu, Gordon Scott M, Drake Steven K, Pryor Milton, Sampson Maureen L, Yang Ling, Freeman Lita A, Remaley Alan T

Abstract excerpt

Apolipoprotein C-II (apoC-II) is a cofactor for lipoprotein lipase, a plasma enzyme that hydrolyzes triglycerides (TGs). ApoC-II deficiency in humans results in hypertriglyceridemia. We used zinc finger nucleases to create Apoc2 mutant mice to investigate the use of C-II-a, a short apoC-II mimetic peptide, as a therapy for apoC-II deficiency. Mutant mice produced a form of apoC-II with an uncleaved signal peptide...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Amino Acid Sequence
Share to Apolipoprotein C-II

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Hyperlipoproteinemia Type I

Share to Hypertriglyceridemia

Share to Mice, Inbred C57BL

Share to Peptide Fragments

Share to Pregnancy

Share to Triglycerides

Source

Open in PubMed Open full text

Identifiers

PMID: 26574515
DOI: 10.1124/jpet.115.229740
PMCID: PMC4727155

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Creation of Apolipoprotein C-II (ApoC-II) Mutant Mice and Correction of Their Hypertriglyceridemia with an ApoC-II Mimetic Peptide.PMID 26574515Read ↗

Apoc2 loss-of-function zebrafish mutant as a genetic model of hyperlipidemia.Semantic proximity Read ↗

Apolipoprotein C-II: New findings related to genetics, biochemistry, and role in triglyceride metabolism.Semantic proximity Read ↗

Dramatically decreased high density lipoprotein cholesterol, increased remnant clearance, and insulin hypersensitivity in apolipoprotein A-II knockout mice suggest a complex role for apolipoprotein A-II in atherosclerosis susceptibility.Semantic proximity Read ↗

Hypertriglyceridemia as a Result of Human apo <i>CII</i> Gene Expression in Transgenic MiceSemantic proximity Read ↗

Inhibition of ApoCIIISemantic proximity Read ↗

Severe hypertriglyceridemia in human APOC1 transgenic mice is caused by apoC-I-induced inhibition of LPL.Semantic proximity Read ↗

A review of the role of apolipoprotein C-II in lipoprotein metabolism and cardiovascular disease.Semantic proximity Read ↗

Role of apoA-II in lipid metabolism and atherosclerosis: advances in the study of an enigmatic protein.Semantic proximity Read ↗

Apolipoprotein CI causes hypertriglyceridemia independent of the very-low-density lipoprotein receptor and apolipoprotein CIII in mice.Semantic proximity Read ↗

Expression of human apolipoprotein A-II in apolipoprotein E-deficient mice induces features of familial combined hyperlipidemia.Semantic proximity Read ↗

ABCA1 Promotes the de Novo Biogenesis of Apolipoprotein CIII-Containing HDL Particles in Vivo and Modulates the Severity of Apolipoprotein CIII-Induced HypertriglyceridemiaSemantic proximity Read ↗

Reduced cholesterol and triglycerides in mice with a mutation in Mia2, a liver protein that localizes to ER exit sites.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.